MAP US

August 1, 2018August 1, 2018

RHB-104 Shows Promise for Crohn’s Disease Remission in Phase 3 Trial

News

RedHill Biopharma’s experimental therapy RHB-104 significantly increases the remission and response rates of patients with Crohn’s disease, according to top-line Phase 3 trial results recently announced by the company. The ... Read more

November 15, 2017November 15, 2017

RedHill Biopharma Wraps Up Recruitment for Phase 3 Trial of RHB-104 for Crohn’s

News

RedHill Biopharma has finished recruiting the 331 participants it wanted for a Phase 3 clinical trial of RHB-104 as a treatment for Crohn’s disease. About two-thirds of the participants have already completed the ... Read more

August 2, 2017August 18, 2017

Phase 3 Trial of RHB-104 as Combination Therapy for Moderate to Severe Crohn’s Is on Track, Review Board Says

Crohn's Disease, News

An independent review board has confirmed the preliminary findings of a Phase 3 clinical trial showing that RHB-104 is a safe and effective combination treatment for Crohn’s disease. The Data ... Read more

June 17, 2015September 28, 2016

RedHill Announces MHRA Acceptance of Clinical Trial Application for Phase III clinical trial of RHB-104 in Crohn’s Disease

Crohn's Disease, News

RedHill Biopharma Ltd., an emerging biopharmaceutical company based in Israel focused on the development of small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, recently announced that the UK ... Read more

December 4, 2014December 4, 2014

RedHill Funds Israeli IBD Society Meeting and Presents Crohn’s Study

IBD News, News

The Israeli company RedHill Biopharma Ltd. is sponsoring the Israeli Inflammatory Bowel Disease Society meeting, which is taking place on December 9th at the Dan Hotel in Tel-Aviv, Israel. The company’s role as sponsor ... Read more